What do systematic reviews say?

Fondaparinux vs variable dose warfarin

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 236 participants
  Very low

Fondaparinux vs placebo

Fondaparinux leads to lower symptomatic VTE compared with placebo (high certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.15 [0.06, 0.36]
  8 studies · 6503 participants
  High

Fondaparinux vs 1 mg warfarin

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 236 participants
  Very low

Fondaparinux vs edoxaban

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Fondaparinux vs mechanical thromboprophylaxis

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 120 participants
  Low

Fondaparinux vs low molecular weight heparin

Fondaparinux showed no clear difference in symptomatic VTE compared with LMWH (moderate certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 1.03 [0.65, 1.63]
  9 studies · 12240 participants
  Moderate

Fondaparinux vs placebo

Fondaparinux probably leads to lower symptomatic VTE Ventilation‐perfusion scanning, helical computed… compared with placebo (moderate certainty).

• Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
  RR 0.15 [0.04, 0.5]
  1 study · 3002 participants
  Moderate